Receiving Allogeneic Hematopoietic Cell TransplantsNCT05404009
Collecting Dietary Information From People Undergoing Cancer Treatment
An observational study of Receiving Allogeneic Hematopoietic Cell Transplants, run by Memorial Sloan Kettering Cancer Center at 1 site in United States.
Trial summary
The purpose of this study is to develop a secure method of collecting dietary and nutritional intake information from people with cancer. The researchers will use this information to learn more about how dietary information may relate to cancer diagnosis and response to treatment, and to identify factors that may lead… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Receiving Allogeneic Hematopoietic Cell Transplants
- How many people
- 150 participants
- Where
- 1 siteUnited States
- Study dates
- 31 May 2022to May 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: Several prospective subcohorts of patients will be recruited in a rolling fashion. The first 3 subcohorts will comprise allo-HCT, auto-HCT, and CAR-T recipients.
Who may be able to join
- Patient is receiving or planning to receive therapy for cancer.
- Patient (or caregiver) has sufficient English proficiency.
Who cannot join
- None
Trial locations and contacts
1 site in 1 country.
United States1 site
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065
About this study
Official title: Prospective, Digitized Dietary Intake Monitoring in Individuals Undergoing Cancer Therapy
The purpose of this study is to develop a secure method of collecting dietary and nutritional intake information from people with cancer. The researchers will use this information to learn more about how dietary information may relate to cancer diagnosis and response to treatment, and to identify factors that may lead to higher or lower risk of cancer.
- Keywords
- Dietary Intake Monitoring, 22-149
What is being measured
The primary outcome is the main question the study is designed to answer.
establish a prospective database
of nutritional intake data from immunotherapy patients that can be paired with the fecal and blood biospecimens already being collected under other protocols (06-107, 16-834) for the purpose of conducting studying correlations between nutrition, gut microbiome, and clinical outcomes.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jun 2022
- Study start31 May 2022
- Primary completionMay 2027 (estimated)
- Study completionMay 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Receiving Allogeneic Hematopoietic Cell TransplantsStudies of the same condition, open and under way.
- More trials run by Memorial Sloan Kettering Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jonathan Peled, MD, PhD, Principal investigator, Memorial Sloan Kettering Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05404009
- Sponsor's protocol ID
- 22-149
- Status last verified
- Apr 2026
- First submitted
- 31 May 2022
- Last updated
- 6 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective, Digitized Dietary Intake Monitoring in Individuals Undergoing Cancer Therapy
- ClinicalTrials.gov ID
- NCT05404009
- Acronym / sponsor ID
- 22-149
- Keywords
- Dietary Intake Monitoring, 22-149
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterUniversity, hospital or other
- Study start
- 31 May 2022 (actual)
- Primary completion
- May 2027 (estimated)
- Study completion
- May 2027 (estimated)
- First posted
- 3 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to develop a secure method of collecting dietary and nutritional intake information from people with cancer. The researchers will use this information to learn more about how dietary information may relate to cancer diagnosis and response to treatment, and to identify factors that may lead to higher or lower risk of cancer.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- Several prospective subcohorts of patients will be recruited in a rolling fashion. The first 3 subcohorts will comprise allo-HCT, auto-HCT, and CAR-T recipients.
Key inclusion criteria (2 listed)
- Patient is receiving or planning to receive therapy for cancer.
- Patient (or caregiver) has sufficient English proficiency.
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
establish a prospective database
Time frame: 2 years
of nutritional intake data from immunotherapy patients that can be paired with the fecal and blood biospecimens already being collected under other protocols (06-107, 16-834) for the purpose of conducting studying correlations between nutrition, gut microbiome, and clinical outcomes.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2026.
- Memorial Sloan Kettering Cancer CenterLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Related trials for Receiving Allogeneic Hematopoietic Cell Transplants
RecruitingPhase 1/2
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant
Cytomegaloviral Infection, Hematopoietic Cell Transplant Recipient
RecruitingPhase 1/2
Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant
E Coli Infections, Allogenic Transplant Patients
RecruitingPhase 2
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Hematologic Malignancies
Active, not recruiting
Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors
Hematopoietic Stem Cell Transplantation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jonathan Peled, MD, PhD principal investigator
Memorial Sloan Kettering Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Receiving Allogeneic Hematopoietic Cell Transplants, run by Memorial Sloan Kettering Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 6 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
establish a prospective database (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2026.